A Framework to Evaluate the Cost-Effectiveness of the NADiA ProsVue Slope to Guide Adjuvant Radiotherapy among Men with High-Risk Characteristics Following Prostatectomy for Prostate Cancer

Abstract

The effect of the ProsVue system on costs will be dependent on the extent to which ART decreases among men identified as having a low risk of recurrence. Its effect on QALYs will remain conditional on uncertain clinical and quality-of-life benefits associated with ART.

Health Economic Evidence for Liquid- and Tissue-based Molecular Tests that Inform Decisions on Prostate Biopsies and Treatment of Localised Prostate Cancer: A Systematic Review

“…Fourteen studies (64%) focused on the use of tests to inform biopsies [20] , [21] , [22] , [23] , [24] , [25] , [26] , [27] , [28] , [29] , [30] , [31] , [32] , [33] , that is, whether an initial or repeat biopsy was to be performed, whereas eight studies (36%) focused on the use of tests for risk stratification to inform treatment decisions [34] , [35] , [36] , [37] , [38] , [39] , [40] , [41] . Table 1 , Table 2 provide an overview of a subset of the data extracted for tests aimed at informing biopsies and treatment of PCa, respectively.…”

“…Tests were mostly evaluated for use in the USA (10/22 studies, 45%) [35] , [22] , [26] , [27] , [28] , [36] , [37] , [38] , [40] , [41] , followed by France ( n = 3, 14%) [23] , [30] , [31] and then Germany [21] , [30] , Spain [20] , [30] , and the UK [33] , [34] ( n = 2, each, 9%). Canada [39] , England and Wales [24] , Hong Kong [29] , Italy [30] , The Netherlands [25] , and Sweden [32] were each the perspective in one study.…”

“…Nine studies (41%) reported industry funding [23] , [26] , [30] , [31] , [33] , [34] , [35] , [37] , [40] . Another six studies (27%) did not disclose any funding source [22] , [25] , [27] , [28] , [36] , [38] , but three of these studies included authors with industry or consultancy affiliations [22] , [27] , [38] . Eleven studies (50%) were published relatively recently, from 2017 onwards.…”

“…Eleven studies (50%) were published relatively recently, from 2017 onwards. Most publications were in medical journals ( n = 15, 68%) [20] , [21] , [25] , [27] , [28] , [30] , [31] , [33] , [34] , [35] , [37] , [38] , [40] , [41] , followed by health policy journals ( n = 6, 27%) [22] , [23] , [24] , [32] , [36] , [39] and multidisciplinary journals ( n = 1, 5%) [29] .…”

What Can Be Expected from Prostate Cancer Biomarkers A Clinical Perspective

“…Indeed, in multicentre, riskstratified cohort ProsVue PSA slope ≤2 pg/mL/month reduced secondary treatment recommendations (ART or ADT), which in turn implied possible health-care costs reduction [120]. However, in cost-effectiveness analysis, ProsVue impact on costs is speculated to depend on the extent to which ART will be reduced in patients with low risk of recurrence and remains uncertain when related to quality-adjusted life years [121]. Although ProsVue received US premarket clearance in 2011, it is yet to be approved by FDA.…”